Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Reference only. Not financial advice. No brokerage order is placed.
Independent agent review — valuation, statement audit, and earnings read on the latest filing.
VTGN is a distressed clinical-stage biotech in active restructuring after a probable mid-2026 trial failure; serial ATM dilution, a $0.17 all-time-low print, and a cost-exit 8-K make this a avoid/monitor-only situation with no near-term catalyst visible in the data bundle.
Bull case: Post-restructuring, a leaner cost structure could extend runway long enough to surface pipeline data or attract a strategic partner/acquirer for remaining IP. The Sep 23 spike (575M volume, price touching $0.55) shows speculative interest still exists — a deal announcement or FDA interaction could generate another tradeable pop from $0.17.
Bear case: The restructuring does not solve the fundamental problem: no revenue, no approved product, and a balance sheet likely gutted by serial ATM draws. The stock is in a confirmed downtrend hitting fresh lows daily with near-zero news coverage and a momentum score of 19. Without an imminent catalyst (partnership, licensing, or data readout), dilutive death-spiral dynamics typically compress the share price toward Nasdaq minimum bid threshold ($1.00 is already breached) and eventual delisting or reverse split — both destructive to new shareholders.
| Date | List | Next-day max run | Next-day close | Hit +2%? |
|---|---|---|---|---|
| 2026-10-12 | sec_top_gappers | +0.0% | -8.7% | — |
| 2026-10-12 | sec_top_moat_emerging | +0.0% | -8.7% | — |
| 2026-09-24 | sec_top_gappers | +0.0% | -10.0% | — |
| 2026-09-24 | sec_top_moat_emerging | +0.0% | -10.0% | — |
| 2026-09-22 | sec_clean_gappers | +120.0% | +48.0% | ✓ hit |
| 2026-09-22 | sec_top_gappers | +120.0% | +48.0% | ✓ hit |
| 2026-09-22 | sec_top_moat_emerging | +120.0% | +48.0% | ✓ hit |
No recent earnings event.
You came here for VTGN. You found it after it moved, the same way everyone else did.
Tier 1 setups touched +2% intraday 44.0% of the time across 414 tracked calls. Baseline for everything else: 38.4%. That is a +5.6 point edge, measured from the NEXT OPEN — the first price you could actually pay, not the prior close. We publish the misses too: https://catalystedgescanner.com/trust/
30 of 30 founding seats left. The price goes up when they are gone.
Become a Founding Member — $99 onceOne payment, access for as long as we run the service. The free daily picks stay free — this is for people who want the full console. Not buying today? Get tomorrow's ranked list free →